Literature DB >> 12499780

Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 workshop.

J Bjerner1, Y Lebedin, L Bellanger, M Kuroki, J E Shively, T Varaas, K Nustad, S Hammarström, O P Børmer.   

Abstract

To characterize antigenic sites in carcinoembryonic antigen (CEA) further and to investigate whether there are differences between colon tumor CEA and meconium CEA (NCA-2) that can be detected by anti-CEA monoclonal antibodies (MAb), 19 new anti-CEA MAb were analyzed with respect to specificity, epitope reactivity and affinity. Their reactivities were compared with 10 anti-CEA MAb with known CEA-domain binding specificity that have previously been classified into five nonoverlapping epitope groups, GOLD 1-5. Cross-inhibition assays with antigen-coated microtiter plates and immunoradiometric assays were performed in almost all combinations of MAbs, using conventionally purified CEA (domain structure: N-A1B1-A2B2-A3B3-C) from liver metastasis of colorectal carcinomas, recombinant CEA, meconium CEA (NCA-2), truncated forms of CEA and NCA (CEACAM6) as the antigens. The affinity of the MAbs for CEA was also determined. The new MAbs were generally of high affinity and suitable for immunoassays. Three new MAbs were assigned to GOLD epitope group 5 (N-domain binding), 3 MAbs to group 4 (A1B1 domain), 1 to group 3 (A3B3 domain), 3 to group 2 (A2B2 domain) and 3 to group 1 (also the A3B3 domain). Three MAbs formed a separate group related to group 4, they were classified as GOLD 4' (A1B1 domain binding). The remaining 3 MAbs appear to represent new subspecificities with some relationship to GOLD groups 1, 2 or 4, respectively. Five MAbs, all belonging to epitope group 1 and 3, reacted strongly with tumor CEA but only weakly or not at all with meconium CEA, demonstrating that the two products of the CEA gene differ from each other, probably due to different posttranslational modifications. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12499780     DOI: 10.1159/000067255

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients.

Authors:  Kristina Schee; Kjersti Flatmark; Ruth Holm; Kjetil Boye; Elisabeth Paus
Journal:  Tumour Biol       Date:  2011-10-18

2.  Coexpression of carcinoembryonic antigen and E-cadherin in colorectal adenocarcinoma with liver metastasis.

Authors:  Jin C Kim; Seon A Roh; Hee C Kim; Kum H Koo; Young K Cho; Chang S Yu; Young M Kwon; Jung S Kim
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

3.  Immunoliposome-PCR: a generic ultrasensitive quantitative antigen detection system.

Authors:  Junkun He; David L Evers; Timothy J O'Leary; Jeffrey T Mason
Journal:  J Nanobiotechnology       Date:  2012-06-22       Impact factor: 10.435

4.  Factors Requiring Adjustment in the Interpretation of Serum Carcinoembryonic Antigen: A Cross-Sectional Study of 18,131 Healthy Nonsmokers.

Authors:  Hae Yeon Kang; Eun Kyung Choe; Kyu Joo Park; Young Lee
Journal:  Gastroenterol Res Pract       Date:  2017-05-16       Impact factor: 2.260

5.  Cutoff values of preoperative s-CEA levels for predicting survivals after curative resection of colorectal cancer.

Authors:  In Ja Park; Hee Cheol Kim; Chang Sik Yu; Jang Hak Yoo; Jin Cheon Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

6.  The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.

Authors:  Li Peng; Michael D Oberst; Jiaqi Huang; Philip Brohawn; Chris Morehouse; Kristen Lekstrom; Patrick A Baeuerle; Herren Wu; Yihong Yao; Steven R Coats; William Dall'Acqua; Melissa Damschroder; Scott A Hammond
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

7.  Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.

Authors:  Maciej Kujawski; Mark Sherman; Susanta Hui; Darren Zuro; Wen-Hui Lee; Paul Yazaki; Anakim Sherman; Barbara Szpikowska; Junie Chea; Desiree Lasiewski; Kofi Poku; Harry Li; David Colcher; Jeffrey Wong; John E Shively
Journal:  Oncoimmunology       Date:  2020-02-14       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.